| News & Announcements | Waiver of certain requirements during COVID-19 outbreak related to Durable Medical Equipment (DME), prosthetics, orthotics, and supplies for Medicare Advantage members (Updated December 15, 2021) | | | | | | 8/2/2022 | | | Waiver of certain requirements during COVID-19 outbreak related to Durable Medical Equipment (DME), prosthetics, orthotics, and supplies for Medicare Advantage members (Updated December 15, 2021) | |
| News & Announcements | Laboratory Testing, Vaccination, and Treatment for Monkeypox for Medicare Advantage Members | | | | | | 8/24/2022 | | | Laboratory Testing, Vaccination, and Treatment for Monkeypox for Medicare Advantage Members | |
| News & Announcements | Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Medicare Advantage Members (Updated August 25, 2022) | | | | | | 8/25/2022 | | | Pharmaceutical Prophylaxis and Treatments of COVID-19 for Independence Medicare Advantage Members (Updated August 25, 2022) | |
| Notifications | Nebulizers and Inhalation Solutions | MA05.007e | 8/5/2022 9:00 AM | 9/5/2022 | | | 8/5/2022 | Medical Necessity Criteria | | Nebulizers and Inhalation Solutions | |
| Notifications | Durable Medical Equipment (DME) | MA05.044l | 8/5/2022 2:00 PM | 9/5/2022 | | | 8/5/2022 | Coverage and/or Reimbursement Position;Medical Coding | | Durable Medical Equipment (DME) | |
| Notifications | Hospital Beds and Accessories | MA05.002e | 8/12/2022 9:00 AM | 9/12/2022 | | | 8/12/2022 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Hospital Beds and Accessories | |
| Notifications | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | MA08.091d | 8/30/2022 10:00 AM | 11/28/2022 | | | 8/30/2022 | Medical Necessity Criteria | | Aprepitant (Cinvanti™), Fosaprepitant Dimeglumine (Emend®), Granisetron (Sustol®), and Rolapitant (Varubi®) | |
| Updated Policies | Radiologic Guidance and/or Supervision and Interpretation of a Procedure | MA00.019j | | 8/1/2022 | | | 8/1/2022 | Medical Coding | | Radiologic Guidance and/or Supervision and Interpretation of a Procedure | |
| Updated Policies | Home Prothrombin Time Monitoring | MA05.016g | 7/15/2022 9:00 AM | 8/15/2022 | | | 8/15/2022 | Medical Coding;General Description, Guidelines, or Informational Update | | Home Prothrombin Time Monitoring | |
| Updated Policies | Wheelchair Cushions and Seating | MA05.023b | 7/15/2022 9:00 AM | 8/15/2022 | | | 8/15/2022 | General Description, Guidelines, or Informational Update | | Wheelchair Cushions and Seating | |
| Updated Policies | Sacituzumab govitecan-hziy (TrodelvyTM) | MA08.118d | | 8/15/2022 | | | 8/15/2022 | Medical Necessity Criteria | | Sacituzumab govitecan-hziy (TrodelvyTM) | |
| Updated Policies | Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®) | MA08.079j | | 8/15/2022 | | | 8/15/2022 | Medical Necessity Criteria;Medical Coding;General Description, Guidelines, or Informational Update | | Daratumumab (Darzalex®), Daratumumab, and Hyaluronidase-fihj (Darzalex Faspro®) | |
| Updated Policies | Asparaginase erwinia chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) | MA08.085f | | 8/15/2022 | | | 8/15/2022 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | Asparaginase erwinia chrysanthemi (Erwinaze®), asparaginase erwinia chrysanthemi (recombinant)-rywn (Rylaze™) | |
| Updated Policies | Radiofrequency, Cryosurgical and Microwave Ablation of Lung Tumors | MA11.052c | | 8/15/2022 | | | 8/15/2022 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | Radiofrequency, Cryosurgical and Microwave Ablation of Lung Tumors | |
| Updated Policies | Lipectomy and Liposuction | MA11.070c | | 8/15/2022 | | | 8/15/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | Lipectomy and Liposuction | |
| Updated Policies | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | MA08.049j | | 8/29/2022 | | | 8/29/2022 | Medical Necessity Criteria | | Paclitaxel Protein-Bound Particles for Injectable Suspension (Albumin-Bound)/(Abraxane® for Injectable Suspension) | |
| Updated Policies | Outpatient Physical Medicine and Rehabilitation Services- Physical Therapy (PT) and Occupational Therapy (OT) | MA10.003i | | 8/29/2022 | | | 8/29/2022 | Coverage and/or Reimbursement Position;Medical Coding | | Outpatient Physical Medicine and Rehabilitation Services- Physical Therapy (PT) and Occupational Therapy (OT) | |
| Updated Policies | Screening for Vertebral Fracture with Dual-Energy X-ray Absorptiometry (DEXA/DXA) | MA09.013b | | 8/29/2022 | | | 8/29/2022 | Medical Coding | | Screening for Vertebral Fracture with Dual-Energy X-ray Absorptiometry (DEXA/DXA) | |
| Updated Policies | Home Health Care Services | MA02.003c | | 8/29/2022 | | | 8/29/2022 | Coverage and/or Reimbursement Position;Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | Home Health Care Services | |
| Updated Policies | Magnetic Resonance Imaging (MRI)--Guided Focused Ultrasound Ablation | MA09.021e | | 8/29/2022 | | | 8/29/2022 | Medical Necessity Criteria;General Description, Guidelines, or Informational Update | | Magnetic Resonance Imaging (MRI)--Guided Focused Ultrasound Ablation | |
| Updated Policies | Percutaneous Image-Guided Lumbar Decompression (PILD) for Spinal Stenosis | MA11.097e | | 8/29/2022 | | | 8/29/2022 | Coverage and/or Reimbursement Position | | Percutaneous Image-Guided Lumbar Decompression (PILD) for Spinal Stenosis | |
| Reissue Policies | Trigger Point Injections | MA11.017h | | 10/1/2021 | 7/27/2022 | | 8/1/2022 | | | Trigger Point Injections | |
| Reissue Policies | Moxetumomab pasudotox-tdfk (Lumoxiti™) | MA08.103b | | 10/1/2019 | 8/10/2022 | | 8/15/2022 | | | Moxetumomab pasudotox-tdfk (Lumoxiti™) | |
| Reissue Policies | Steroid-Eluting Sinus Stents and Implants | MA11.107f | | 9/13/2021 | 8/24/2022 | | 8/24/2022 | | | Steroid-Eluting Sinus Stents and Implants | |
| Reissue Policies | Electron Beam Computed Tomography (EBCT) for Screening Evaluations | MA09.011b | | 8/2/2021 | 8/24/2022 | | 8/25/2022 | | | Electron Beam Computed Tomography (EBCT) for Screening Evaluations | |
| Reissue Policies | Nonemergent Inpatient Video Electroencephalogram (EEG) Monitoring and Ambulatory EEG Monitoring in the Home | MA07.053a | | 1/1/2020 | 8/24/2022 | | 8/25/2022 | | | Nonemergent Inpatient Video Electroencephalogram (EEG) Monitoring and Ambulatory EEG Monitoring in the Home | |
| Reissue Policies | Endovascular Stent-Graft Repair of Thoracic Aortic Aneurysms and Nonaneurysmal Lesions | MA11.062a | | 1/1/2022 | 8/24/2022 | | 8/25/2022 | | | Endovascular Stent-Graft Repair of Thoracic Aortic Aneurysms and Nonaneurysmal Lesions | |
| Reissue Policies | Acupuncture | MA12.004c | | 10/1/2021 | 8/24/2022 | | 8/25/2022 | | | Acupuncture | |
| Reissue Policies | Erythropoiesis Stimulating Agents (ESAs) | MA08.011f | | 9/27/2021 | 8/24/2022 | | 8/26/2022 | | | Erythropoiesis Stimulating Agents (ESAs) | |
